|
Last
updated February 10, 2005
Saturday, MAY 14
1:00pm–3:00pm
4652—Neonatal
Infectious Disease and Inflammation
PAS Original Science Abstracts -
Platform Session
1:00pm–3:00pm
4654—Pulmonary
Vascular Biology
PAS Original Science Abstracts -
Poster Symposium
3:15pm–5:15pm
4842—Fetal
Origins of Adult Disease
PAS Original Science Abstracts -
Poster Symposium
3:15pm–5:15pm
4851—Pathogenesis
of Bronchopulmonary Dysplasia
PAS Original Science Abstracts -
Platform Session
Sunday, MAY 15
7:00am–8:00am
5057—Pulmonology
Career Development in Pediatric Pulmonary Medicine
PAS Meet the Professor Breakfast
Steven H. Abman, University of Colorado School of Medicine,
Denver, CO
This session will discuss issues in career
development for trainees and junior faculty who are
interested in pediatric pulmonary and critical care
medicine. Discussion will focus on issues regarding
training in clinical research, expanding laboratory
research skills, meeting clinical and research committees,
balancing career with life style, developing
collaborations, mentorship and related questions.
Target Audience: Trainee, junior faculty.
8:00am–10:00am
5101—ARDS:
New Pathways and Treatments
PAS Topic Symposium
Chairs:
Steven H. Abman, University of Colorado School of
Medicine, Denver, CO; and Alan Jobe, Cincinnati Children's
Hospital Medical Center, Cincinnati, OH
Acute respiratory distress syndrome (ARDS) remains a
leading cause of morbidity and death in critically ill
neonates, infants and children. ARDS is associated with
diverse clinical disorders, including sepsis, trauma,
aspiration and infection and is characterized by lung
inflammation, non-hydrostatic pulmonary edema and poor
lung compliance. Recent advances in the basic pathobiology
of lung injury have led to new insights into the etiology
and potential therapeutic approaches toward ARDS. In
addition, recent clinical studies have examined
differences between adult and pediatric ARDS, genetic
susceptibility factors that may increase the risk for ARDS,
interactive cellular and physiologic mechanisms that cause
progressive lung injury and the role of different
strategies of mechanical ventilation that can adversely or
favorably determine the clinical outcomes of patients with
ARDS. This symposium includes leading experts in the field
of lung biology and critical care who will present state
of the art information on basic pathophysiologic
mechanisms of ARDS and new therapeutic approaches. These
integrated topics are of marked interest to intensivists,
neonatologists, pulmonologists, infectious disease and
basic scientists in the field of lung biology.
Target Audience: Scientists and clinicians interested
in basic mechanisms underlying the pathophysiology of
acute lung injury and clinical strategies in the
management of acute hypoxemic respiratory failure in
neonates, infants and children.
New Insights into ARDS
Michael
Matthay, University of California San Francisco Medical
School, San Francisco, CA
Mechanisms of Tissue Injury in Sepsis/ARDS
Hector
R. Wong, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
Role of Permissive Hypercapnea in Acute Lung Injury
Brian
Kavanagh, Hospital for Sick Children, Toronto, ON, Canada
Novel Ventilator Strategies in ARDS
John
H. Arnold, Children's Hospital, Boston, MA
8:00am–10:00am
5140—Childhood
Asthma
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
5150—Vascular
Mediators in Persistent Pulmonary Hypertension
PAS Original Science Abstracts -
Platform Session
8:00am–11:00am
5201—New
Care Models for Inner-City Asthma: How Expanding the
Primary Care Role of the Pediatric Emergency Department
Can Improve Patient Outcomes
PAS Mini Course
Chairs:
Ellen F. Crain, Albert Einstein College of Medicine and
Jacobi Medical Center, Bronx, NY; and Sandra J.
Cunningham, Albert Einstein College of Medicine and Jacobi
Medical Center, Bronx, NY
The prevalence of and morbidity from asthma is
especially high among inner-city children, and these
children disproportionately use the emergency department
(ED) for care. While EDs provide excellent acute care,
they are not equipped to provide the preventive care that
these children need. There is a debate in the pediatric ED
community about how much primary care is appropriate for
the ED to take on, but most efforts in primary care
settings to reduce ED use by inner-city children with
asthma have not worked. In this session, participants will
learn about several successful pediatric ED interventions
to reduce ED use by inner-city children, which have
required the addition of relatively modest primary care
activities. The interventions, as well as their human,
financial and implementation costs, and likely success in
other settings will be described.
Target Audience: Pediatric emergency medicine
physicians, pulmonologists, epidemiologists, health
service researchers.
Incorporating Primary Care into Emergency Department
Treatment of Children with Asthma
Sandra
J. Cunningham, Albert Einstein College of Medicine, Jacobi
Medical Center, Bronx, NY
Successful Emergency Department Strategies To Improve
Long-Term Care for Children with Asthma
Joseph
J. Zorc, Children's Hospital of Philadelphia,
Philadelphia, PA
The Asthma Coach Program
Sharon
R. Smith, Connecticut Children's Medical Center, Hartford,
CT
The Fast Track Clinic: An Emergency Department
Intervention To Reduce Morbidity Among Children with
Asthma
Stephen
J. Teach, Children's National Medical Center, Washington,
DC
Discussion
11:45am–1:45pm
Poster
Session II
PAS Original Science Abstracts -
Poster Session
Pulmonology:
5460—General
Neonatology:
5465—Apnea—Respiratory Control
5466—Control of Breathing
2:00pm–4:00pm
5521—Regulation
of Alveolar Epithelial Repair—or, How Do We Put It All
Back Together Again
PAS Topic Symposium
Chairs:
Rita Ryan, State University of New York at Buffalo, Women
and Children's Hospital of Buffalo, Buffalo, NY; and Heber
Nielsen, Tufts University School of Medicine, Tufts-New
England Medical Center, Boston, MA
Regulation of alveolar epithelial repair after many
forms of lung injury remains incompletely understood. The
type II cell is an important source of growth factors and
there are autocrine and paracrine mediators that are
altered during the repair process. Type I cells are the
primary covering of the alveolar epithelium, and their
restoration is critical to recapitulate normal repair.
This symposium will focus on the fundamental mechanisms of
epithelial repair after injury and examine connections
with lung development. Finally, relevance to current
clinical disease will be discussed.
Target Audience: Physician and basic scientists
interested in how the alveolar epithelium repairs itself
after injury and the relationship of lung repair with lung
development.
Introduction
Rita
M. Ryan, State University of New York at Buffalo, Women
and Children's Hospital of Buffalo, Buffalo, NY
Heber C. Nielsen, Tufts New England Medical Center,
Boston, MA
Type II Cell Mitogens
Timothy
D. Le Cras, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
Type II Cell Proliferation During Lung Injury and
Repair
Michael
A. O'Reilly, University of Rochester, Rochester, NY
Type I Cells in Alveolar Repair
Susan
H. Guttentag, Children's Hospital of Philadelphia,
Philadelphia, PA
Apoptosis in Alveolar Epithelial Repair
Lin
L. Mantell, Institute for Medical Research at North
Shore-Long Island Jewish, New York University School of
Medicine, Manhasset, NY
Translating Alveolar Epithelial Repair Fundamentals
to the Bedside
John
S. Torday, Los Angeles Biomedical Research Institute at
Harbor-UCLA Medical Center, Torrance, CA
2:00pm–4:00pm
5535—Neonatal
Epidemiology and Follow-up
PAS Original Science Abstracts -
Platform Session
4:15pm–5:45pm
5702—Identification
of Asthma-Susceptibility Genes and Implications for New
Pharmaceutical Development
PAS State of the Art Plenary
Chair:
Clifford W. Bogue, Yale University School of Medicine, New
Haven, CT
Asthma is rapidly emerging as a major public health
disorder in childhood. Innovative strategies combining
genetic mapping and gene expression profiling are
providing the tools to identify genes that underpin asthma
predisposition. This presentation not only has relevance
for an important pediatric medical topic, but also
establishes a paradigm that can be used for other complex
genetic disorders that affect children.
Target Audience: This session will be of interest to
a broad audience including practicing pediatricians,
geneticists, pulmonologists, pharmacologists, critical
care specialists and allergist/immunologists
Marsha Wills-Karp, Children's Hospital Medical
Center, Cincinnati, OH
4:15pm–6:15pm
5743—Pediatric
Nutrition and Metabolism
PAS Original Science Abstracts -
Platform Session
Monday, MAY 16
8:00am–10:00am
6101—Understanding
the New Pediatric Morbidities: Evidence from the Centers
for Children’s Environmental Health and Disease
Prevention Research
PAS Topic Symposium
Chair:
Ruth A. Etzel, George Washington University School of
Public Health and Human Services, Washington, DC
Learning disorders, ADHD, developmental delay, asthma
and depression are among the chronic conditions referred
to as the “new pediatric morbidities.” There is
growing evidence that environmental disruption and chronic
exposure to synthetic chemicals contribute to these new
morbidities. The 12 Centers for Children’s Environmental
Health and Disease Prevention Research funded by the
National Institute of Environmental Health Sciences and
the U.S. EPA are contributing to our understanding of the
effects of environmental exposures on children’s health.
Participants in this session will learn about findings
related to asthma and neurobehavioral impairment and gain
new understanding of conditions that affect growing
numbers of U.S. children.
Target Audience: Pediatricians, academic generalists,
health services researchers, environmental health
scientists, developmental–behavioral pediatricians and
pediatric pulmonologists.
Centers for Children's Environmental Health and
Disease Prevention Research: Progress Since 1998
Ruth
A. Etzel, George Washington University School of Public
Health and Health Services, Washington, DC
Prenatal Exposure to Pesticides, Maternal Paraoxonase
Levels and Small Heads at Birth: A Possible
Gene–Environment Interaction
Trudy
Berkowitz, Mount Sinai School of Medicine, New York, NY
PCBs, Mercury and Neurobehavioral Impairment
Susan
Schantz, University of Illinois at Urbana-Champaign,
Urbana, IL
Air Pollution, Smoking and Asthma in Southern
California Children
Frank
Gilliland, University of Southern California, Los Angeles,
CA
Discussion
8:00am–10:00am
6132—Clinical
Trials in Perinatal and Neonatal Medicine I
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
6133—Development
Biology
PAS Original Science Abstracts -
Platform Session.
3:00pm–5:00pm
6730—Cardiac
and Pulmonary Development
PAS Original Science Abstracts -
Platform Session
3:00pm–5:00pm
6732—Neonatal
Hyperoxia and the Lung
PAS Original Science Abstracts -
Platform Session
5:15pm–6:45pm
Poster
Session III
PAS Original Science Abstracts -
Poster Session
Neonatal Pulmonology:
6840—Lung Injury
Developmental Biology:
6852—Lung
Neonatal Pulmonology:
6861—Neonatal Ventilating
6862—Bronchopulmonary Dysplasia
Neonatology:
6872—Steroids and Lung Development
6:45pm–8:00pm
6950A—Lung
Club
Club
Oxygen Therapy in the Newborn: Elixir of Life or
Nectar of Death?
Ola
Didrik Saugstad, Professor, Department of Pediatric
Research, Rikshospitalet University Hospital, Oslo, Norway
Contact:
Roberta A. Ballard, M.D.
Children's Hospital of Philadelphia
Phone: 215-590-1653
Email: ballard@email.chop.edu
Sponsored by an educational grant from Ross
Products Division, Abbott Laboratories
Tuesday, MAY 17
8:00am–10:00am
7101—Inner-City
Asthma Intervention Program: Research to Practice
PAS Topic Symposium
Chair:
Pamela R. Wood, University of Texas Health Sciences Center
at San Antonio, San Antonio, TX
The National Cooperative Inner City Asthma
Intervention (NCICAIS) is an asthma counselor (AC),
social-worker-driven intervention for inner-city children
with persistent asthma. Although the AC intervention was
shown to decrease symptom days in a randomized, controlled
trial, there were no data on implementation of this
intervention outside the research setting. In 2001, the
Centers for Disease Control and Prevention funded a 4-year
program to implement the asthma counselor model in 22
sites. This “research to practice” session will
explore lessons learned through the implementation process
and the implications for researchers, clinicians and
policy makers.
Target Audience: General pediatricians,
pulmonologists, allergists and other health professionals
who care for children with asthma; health services
researchers; and program planners.
Introduction
Pamela
R. Wood, University of Texas Health Sciences Center at San
Antonio, San Antonio, TX
NCICAIS Intervention: Differences Between Research
and Clinical Settings
Meyer
Kattan, Mount Sinai School of Medicine, New York, NY
Asthma Risk Factor Assessment: What Are the Needs of
Inner-City Families?
Karen
Warman, Children's Hospital at Montefiore, Albert Einstein
College of Medicine, Bronx, NY
The Asthma Counselor Speaks: Barriers and Successes
Laudy
Rodriguez, Mount Sinai Medical Center, New York, NY
Aligning Incentives For Optimal Asthma Care
Cathy
Carroll, Children's Mercy Hospitals and Clinics, Kansas
City, MO
Discussion
8:00am–10:00am
7102—Transitioning
Complex Pediatric Patients to Adult Care
PAS/ASPN/LWPES Hot Topic
Chair:
Sandra L. Watkins, University of Washington, Seattle, WA
Transitions are a part of everyone's life experience.
Most young people with special health care needs and
disabilities (SHCN/D) become independent members of adult
society, but some need deliberate guidance and support.
With increasing success in reducing the mortality of once
devastating pediatric diseases, the latter group is
growing in number. A new consensus statement from the
American Academy of Pediatrics and the U.S. Federal
Government (Healthy People 2010) has focused attention on
the need to assist young people with SHCN/D in attaining
their potential in adulthood. This symposium will discuss
the growing number of young people with SHCN/D and present
approaches for effecting these transitions. Specific disease-related examples will be used to highlight
the issues, the barriers and the key elements of
successful programs that transition patients from
pediatric care to the adult system.
Target Audience:
All Grown Up and Wondering What To Do: Transitioning
Complex Pediatric Patients to Adult Care
Patience
H. White, George Washington University School of Medicine,
Washington, DC
Transition Best Practices
Cecily
L. Betz, University Center For Excellence in Development
Disabilities, Children's Hospital Los Angeles, CA
Transition to Adult Care in the Nephrology
Population–Renal Failure or Success
Maria
Ferris, University of North Carolina-Chapel Hill, NC
Training and Workforce Issues for Successful
Transition
Roberta
G. Williams, University of Southern California, Los
Angeles, CA
Discussion
Sponsored jointly by the American Society
of Pediatric Nephrology, Lawson Wilkins Pediatric
Endocrine Society and the Pediatric Academic Societies
8:00am–10:00am
7156—Genetic
Basis of Cardiopulmonary Disease
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
7157—Lung
Maturation, Septation and Growth
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
7158—Mechanisms
of Childhood Lung Disease
PAS Original Science Abstracts -
Platform Session
10:15am–11:45am
7301—Genetic
Mechanisms of Respiratory Distress in the Newborn Infant
PAS State of the Art Plenary
Chair:
F. Sessions Cole, Washington University School of
Medicine, St. Louis Children's Hospital, St. Louis, MO
Improved survival of newborn infants with lung
disease has unmasked distinct genetic mechanisms that
contribute to acute, chronic and lethal pulmonary
insufficiency. Mutations in the surfactant protein genes B
and C and a lamellar body transporter gene (ATP-binding
cassette transporter A3 or ABCA3) may disrupt pulmonary
surfactant function and alveolar type 2 pneumocyte
metabolism. After discussing the clinical aspects of the
surfactant protein deficiencies, we will discuss how more
common polymorphisms in the surfactant protein genes may
be related to respiratory distress and our current
understanding of the pathogenetic contribution of
mutations in the ABCA3 gene to both acute neonatal and
chronic interstitial lung disease in children.
Target Audience: Neonatologists, pulmonologists and
geneticists.
Introduction
F.
Sessions Cole, Washington University School of Medicine,
St. Louis Children's Hospital, St. Louis, MO
Clinical Aspects of Surfactant Protein Deficiencies
Aaron
Hamvas, Washington University School of Medicine, St.
Louis Children's Hospital, St. Louis, MO
Polymorphisms in the Surfactant Protein Genes
Mikko
Hallman, University of Oulu, Oulu, Finland
ABCA3 and the Genetic Basis of Interstitial Lung
Disease
Lawrence
M. Nogee, Johns Hopkins School of Medicine, Baltimore, MD
Summary
F.
Sessions Cole, Washington University School of Medicine,
St. Louis Children's Hospital, St. Louis, MO
Supported in part by an unrestricted
educational grant from Dey, LP
12:00pm–1:30pm
Poster
Session IV
PAS Original Science Abstracts -
Poster Session
Neonatal Pulmonology:
7420—Surfactants
7421—Vascular Biology
Neonatology:
7430—Oxygen/Oxidative Stress
7432—Nitric Oxide
1:45pm–3:45pm
7601—New
Therapeutic Strategies for Classical Pediatric Diseases
PAS Hot Topic
Chairs:
David Cornfield, University of Minnesota School of
Medicine, Minneapolis, MN; and Nina F. Schor, Children's
Hospital of Pittsburgh, Pittsburgh, PA
The pathogenesis of numerous single-gene disorders
has been effectively delineated. However, the application
of this knowledge to patient care has lagged far behind.
This symposium will present recent progress made in the
development of therapeutic strategies for four classical
pediatric disorders. First, novel genetic therapies for
hematologic diseases will be discussed. Second,
interventions that reverse the key abnormalities in signal
transduction underlying autosomal dominant polycystic
kidney disease, a leading cause of end-stage renal
disease, will be presented. Third, we will discuss a
treatment strategy that normalizes the intracellular
processing and function of the mutated cystic fibrosis
transmembrane conductance regulator (CFTR), which
underlies the majority of cases of CF. Fourth,
pharmacologic strategies against muscular dystrophy will
be presented. These four innovative approaches provide
great hope for patients suffering from these disorders,
and they serve as exciting examples of potential means to
combat other devastating pediatric conditions.
Target Audience: Scientists and clinicians involved
with the development of new therapeutic strategies for a
variety of childhood disorders.
Embryonic Globins as Therapeutic Agents for
Hemoglobinopathies and Thalassemias
J.
Eric Russell, The Children's Hospital of Philadelphia,
Philadelphia, PA
Novel Therapies for Renal Cystic Diseases
Vicente
E. Torres, Mayo Clinic, Rochester, MN
Treatment of Cystic Fibrosis with Curcumin
Marie
E. Egan, Yale University School of Medicine, New Haven, CT
Pharmacologic Strategies Against Muscular Dystrophy
Tejvir
S. Khurana, University of Pennsylvania School of Medicine,
Philadelphia, PA
1:45pm–3:45pm
7602—Pulmonary
Hypertension: Mechanisms and Management
PAS Hot Topic
Chair:
Steve H. Abman, University of Colorado School of Medicine,
Denver, CO
Pulmonary hypertension contributes significantly to
high morbidity and mortality in diverse clinical settings,
including term or near-term newborns with hypoxemic
respiratory failure, premature infants with RDS,
congenital heart disease, idiopathic or primary pulmonary
hypertension and other diseases. Recent advances in
molecular biology, genetics and physiology have led to
novel therapeutic strategies that are now available for
the treatment of severe pulmonary hypertension. This
symposium will present novel mechanisms in the
pathogenesis of pulmonary hypertension, as well as
critical appraisal of treatment options for neonates,
infants and children with pulmonary hypertension. First,
basic molecular and cellular mechanisms that underlie the
development of pulmonary hypertension will be presented.
This will be followed by a discussion of the physiologic
basis for current therapeutic approaches to persistent
pulmonary hypertension of the newborn and ongoing
controversies in patient management. The next speaker will
discuss the use of inhaled nitric oxide (iNO) in premature
infants. Although approved for use in the term or
near-term neonate with hypoxemic respiratory failure, the
potential role for iNO in premature newborns for the
treatment of acute lung disease or the prevention of
bronchopulmonary dysplasia has been highly controversial.
Finally, we will learn of novel treatment strategies for
children with chronic pulmonary hypertension, including
clinical approaches that utilize separate or combined
therapies, such as prostacyclin analogues, endothelin
receptor antagonists and PDE5 inhibitors.
Target Audience: Scientists and clinicians from
diverse clinical backgrounds, including neonatology,
cardiology, pulmonary medicine and critical care who are
involved with newborns and children with acute and chronic
pulmonary hypertension. This symposium will describe
recent advances in the basic science and clinical
management strategies of pulmonary hypertension.
Novel Mechanisms in the Pathogenesis of Pulmonary
Hypertension
Marlene
Rabinovitch, Stanford University School of Medicine,
Stanford, CA
New Insights in the Pathophysiology and Treatment of
PPHN
Robin
H. Steinhorn, Northwestern University Medical School,
Chicago, IL
Controversies in the Use of Inhaled NO in Premature
Newborns
John
P. Kinsella, University of Colorado School of Medicine,
Children's Hospital, Denver, CO
Novel Therapeutic Strategies for the Treatment of
Pulmonary Hypertension
Robyn
J. Barst, Columbia University College of Physicians &
Surgeons, New York, NY
Supported by an unrestricted educational
grant from INO Therapeutics
|
